August 16, 2022 – GSK completes acquisition of Affinivax, Inc. READ MORE >
simple. powerful.
vaccines.
Novel Vaccines Designed to Enhance the Depth and Breadth of Protection against Challenging Infectious Diseases
Affinivax is a clinical stage biopharmaceutical company with a next generation vaccine technology platform called the Multiple Antigen Presentation System (MAPS). MAPS uses a patented approach to achieve high-affinity binding of two key immunogenic components – polysaccharide and protein antigens – so that both components are able to drive a broad and protective B-cell and T-cell immune response in a single vaccine. We believe the result is a significant step forward in vaccine technology, creating novel preventive and therapeutic vaccines targeting resistant infectious and other immune-mediated diseases.
The time to focus on novel vaccine development is now.
Hear about our bold mission and pioneering company.
Trade marks are owned by or licensed to the GSK group of companies.
©2022 GSK group of companies or its licensor.
